CD274 and non-small cell lung carcinoma: Moreover, in a study of patients with non-small cell lung cancer (NSCLC) treated with the immune checkpoint inhibitors (ICIs) anti-PD1/PD-L1, high levels of antibodies towards type XVII collagen and immune-related adverse events (irAEs) were associated with better response to therapy and longer OS [46].